Grifols SA

OTC:GIKLY

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

Spain ES

Employees

25 000

IPO date

May 17, 2006

Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.

Its customers are hospitals, clinics, pharmacies, blood banks, and medical laboratories. Grifols makes money by selling finished therapies, diagnostic reagents, and testing instruments, and by supplying products and services tied to plasma collection and blood testing. A large part of the business depends on turning donated plasma into specialized treatments that are hard to make and heavily regulated.

What makes Grifols different is that it sits in several parts of the healthcare value chain at once. It collects plasma, processes it into medicines, and also sells diagnostic equipment that helps screen blood and support laboratory testing. That mix gives it a role both as a drug maker and as a supplier to the blood and diagnostics industry.